hossein

Dr. Mahmoud Mirmehrabi

 

Department of Chemical & Biochemical Engineering

Faculty of Engineering

The University of Western Ontario

 
 

Education

 
 

Ph.D

2005

Chemical Engineering, Chemical and Biochemical Engineering Department, The University of Western Ontario, London, Ontario, Canada.

M.Sc.

1999

in Chemical Engineering, Sharif University of Technology, Tehran, Iran.

B.Sc.

1997

in Chemical Engineering, Ferdowsi University of Mashad, Mashad, Iran.

 
 

Professional Experience

 
 
  • Fermentation planner and R&D manager
1999-2001

Iran Mellas Co., Producer of baker's yeast, www.iranmellas.com, Mashad, Iran.

  • Design engineer
1998-1999

Wastewater treatment project, Iran Mellas Co., Producer of baker's yeast, www.iranmellas.com, Mashad, Iran.

 
 
return to top
 
 

Projects

 
 

Project in CCPL:

 
 
  • Develop a thermodynamic and kinetic understanding of the factors controlling the polymorphism in pharmaceutical products using some model compounds.
  • Establish a systematic procedure for polymorphic identification and control.

   Polymorphism is defined as different crystalline forms of an identical chemical substance. The polymorphic behavior of organic solids in pharmaceutical industries is quite important. For example, the bioactivity of two modifications of Chloramphenicol Palmitate can differ by a factor of about 8. So, the conversion of one form to another form during the production and/or storage of drug will cause the weakness of the drug or the danger of extra dosage. The physical properties differing among polymorphs include stability (i.e. shelf life of drug), crystal shape, compressibility, density, dissolution rate (bioavailability), melting point, hardness, optical and electrical properties, vapor pressure, etc.
There are a number of factors, which affect the selectivity of different polymorphs of a given substance in crystallization processes. Some of these factors can be considered as type of solvent, degree of supersaturation, crystallization temperature, rate of cooling, impurities and additives, surface of crystallization vessel, suspended particles, seeding and flow regime.
Selecting some model substances and finding experimentally all the parameters that affect the polymorph selectivity and stability in the first stage and then, finding some general rules for controlling the polymorphism using the attained data and molecular thermodynamics is the objective of this research project.

return to top

 
 
 

Selected Publications

 
 

Journal Articles and Conference Papers:

 

Mirmehrabi, M., S. Rohani , L. Perry, ‘Thermodynamic Modeling and Prediction of Drug Solubility in Solvents: Part 1. A New Activity Coefficient Model', J. Pharmaceutical Sci. , 95(4), 790-797 (2006).

 

Mirmehrabi, M., S. Rohani , L. Perry, ‘Thermodynamic Modeling and Prediction of Drug Solubility in Solvents: Part 2. The New Model, the UNIQUAC and the NRTL Models', J. Pharmaceutical Sci. , 95(4), 798-809 (2006)

 

Mirmehrabi, M., S. Rohani, K.S.K. Murthy and B. Radatus, ‘Polymorphic Behaviour and Crystal Habit of an Anti-Viral/HIV Drug: Stavudine', J. Crystal Growth & Des. 6(1), 141-149(2006).

 

Mirmehrabi, M; Rohani, S. and Jennings M., Single Crystal Studies of Stavudine, Acta Crystallographica, Section C: Crystal Structure Communications, C61(12), o695-o698 (2005).

 

Mirmehrabi, M., S. Rohani ‘An Approach to Solvent Screening for Crystallization of Polymorphic Pharmaceuticals and Fine Chemicals', J. Pharmaceutical Sci. , 94 (7), 1560-1576 (2005)

 

Rohani S. and M. Mirmehrabi, 2004. "Batch Crystallization in Pharmaceutical and Fine Chemicals Industries in Canada", Proceeding of International Technical Forum Inspiring Powder Technology, Tokyo, Japan

 

Mirmehrabi M., S. Rohani, K.S.K Murthy and B. Radatus, 2004. “Improving the Filterability and Solid Density of Ranitidine Hydrochloride Form 1”, Journal of Pharmaceutical Sciences, 93 (7), 1692-1700.

 

Mirmehrabi M., S. Rohani, K.S.K Murthy and B. Radatus, 2004. “Solubility, Dissolution Rate and Phase Transition Studies of Ranitidine Hydrochloride Tautomeric Forms”, International Journal of Pharmaceutics, 282(1-2), 73-85.

 

Mirmehrabi M., S. Rohani, K.S.K. Murthy and B. Radatus, 2004. “Characterization of Tautomeric Forms of Ranitidine Hydrochloride: Thermal Analysis, Solid-State NMR, X-ray”, Journal of Crystal Growth, 260, 517-526

 

Mirmehrabi M. and S. Rohani, 2004. “Measurement and Prediction of the Solubility of Stearic Acid Polymorphs by the UNIQUAC Equation”, Canadian Journal of Chemical Engineering, 82 (2), 335-342.

 

Conferences:

 

Mirmehrabi M. and S. Rohani, 2004. "Molecular Interactions Between Solvent and Pharmaceutical Compounds in Crystallization of Polymorphic Systems", American Institute of Chemical Engineers Conference, Austin, Texas, USA.

 

Mirmehrabi M., S. Rohani, K.S.K. Murthy and B. Radatus, 2003. "Tautomeric Polymorphism of Ranitidine Hydrochloride", 53rd Canadian Chemical Engineering Conference, Hamilton, Canada.

 

Mirmehrabi M. and S. Rohani, 2002. "Control of Polymorphism in Pharmaceutical Products", 52nd Canadian Chemical Engineering Conference, Vancouver, Canada.

 

Rohani S. and M. Mirmehrabi, 2002. "Solid-Liquid Equilibrium of Stearic Acid Polymorphs in Organic Solvents", 52nd Canadian Chemical Engineering Conference, Vancouver, Canada.

 

Mirmehrabi M. and H. A. Seirafi, 2002. "Anaerobic Treatment of Baker's yeast Effluent Using Upflow Anaerobic Sludge Bed (UASB) Pilot", 52nd Canadian Chemical Engineering Conference, Vancouver, Canada.

 

Kermanshahi Pour A., H.A. Seirafi and M. Mirmehrabi, 2002. "Decolorization of Pulp and Paper Wastewater", 52nd Canadian Chemical Engineering Conference, Vancouver, Canada.

 

Mirmehrabi M. and H. Seirafi, 2001. “Biological Wastewater Treatment of Baker’s yeast Plant”, Iranian Chemical Engineering Conference, Isfahan, Iran.

 
 
 
return to top
 

Also from this web page:


Contact Info

Professor Rohani research Group

Thompson Eng. Bld., Rm. 457
Tel: (519) 661-4116
Fax: (519)661-3498